In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores

Gastroenterology

Volumn 151, Issue 6, 2016, Pages 1141-1154.e9

  Schwimmer, Jeffrey B ^a,b,q   Lavine, Joel E ^c,q   Wilson, Laura A ^d   Neuschwander Tetri, Brent A ^e   Xanthakos, Stavra A ^g   Kohli, Rohit ^g,q   Barlow, Sarah E ^h   Vos, Miriam B ⁱ   Karpen, Saul J ⁱ   Molleston, Jean P ^j,q   Whitington, Peter F ^k,q   Rosenthal, Philip ^l,q   Jain, Ajay K ^f   Murray, Karen F ^m   Brunt, Elizabeth M ^n,q   Kleiner, David E ^o,q   Van Natta, Mark ^q   Clark, Jeanne M ^d,q   Tonascia, James ^d,q   Doo, Edward ^p   Abrams, Stephanie H ^q   Barlow, Sarah ^q   Himes, Ryan ^q   Krisnamurthy, Rajesh ^q   Maldonado, Leanel ^q   Mahabir, Rory ^q   Bernstein, Kimberlee ^q   Bramlage, Kristin ^q   Cecil, Kim ^q   DeVore, Stephanie ^q   Lake, Kathleen ^q   Podberesky, Daniel ^q   Towbin, Alex ^q   Xanthakos, Stavra ^q   Behr, Gerald ^q   Lefkowitch, Jay H ^q   Mencin, Ali ^q   Reynoso, Elena ^q   Alazraki, Adina ^q   Cleeton, Rebecca ^q   Karpen, Saul ^q   Cruz Munos, Jessica ^q   Raviele, Nicholas ^q   Vos, Miriam ^q   Bozic, Molly ^q   Cummings, Oscar W ^q   Klipsch, Ann ^q   Munson, Sarah ^q   Sandrasegaran, Kumar ^q   Subbarao, Girish ^q   Kafka, Kimberly ^q   Scheimann, Ann ^q   Amsden, Katie ^q   Fishbein, Mark H ^q   Kirwan, Elizabeth ^q   Mohammad, Saeed ^q   Rigsby, Cynthia ^q   Sharda, Lisa ^q   Derdoy, Jose ^q   Jain, Ajay ^q   King, Debra ^q   Osmack, Pat ^q   Siegner, Joan ^q   Stewart, Susan ^q   Torretta, Susan ^q   Wriston, Kristina ^q   Baker, Susan S ^q   Zhu, Lixin ^q   Africa, Jonathon ^q   Angeles, Jorge ^q   Arroyo, Sandra ^q   Awai, Hannah ^q   Behling, Cynthia ^q   Bross, Craig ^q   Durelle, Janis ^q   Middleton, Michael ^q   Newton, Kimberly ^q   Paiz, Melissa ^q   Sanford, Jennifer ^q   Sirlin, Claude ^q   Ugalde Nicalo, Patricia ^q   Villarreal, Mariana Dominguez ^q   Aouizerat, Bradley ^q   Courtier, Jesse ^q   Ferrell, Linda D ^q   Fleck, Shannon ^q   Gill, Ryan ^q   Langlois, Camille ^q   Perito, Emily Rothbaum ^q   Tsai, Patrika ^q   Cooper, Kara ^q   Horslen, Simon ^q   Hsu, Evelyn ^q   Murray, Karen ^q   Otto, Randolph ^q   Yeh, Matthew ^q   Young, Melissa ^q   Fowler, Kathryn ^q   Brown, Sherry ^q   Doo, Edward C ^q   Hoofnagle, Jay H ^q   Robuck, Patricia R ^q   Sherker, Averell ^q   Torrance, Rebecca ^q   Belt, Patricia ^q   Donithan, Michele ^q   Hallinan, Erin ^q   Isaacson, Milana ^q   May, Kevin P ^q   Miriel, Laura ^q   Sternberg, Alice ^q   Vaughn, Ivana ^q   Wilson, Laura ^q   Yates, Katherine ^q   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h TEXAS CHILDREN S HOSPITAL   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k CHILDREN'S MEMORIAL HOSPITAL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁿ WASHINGTON UNIVERSITY   (United States)

^o NATIONAL CANCER INSTITUTE   (United States)

^p NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^q NONE

more..

Author keywords

ALT; AST; Obesity; Pediatrics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; MERCAPTAMINE; PLACEBO; CYSTINE DEPLETING AGENT; DELAYED RELEASE FORMULATION;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHILD; CLINICAL OUTCOME; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HEPATOBILIARY DISEASE; HUMAN; HUMAN TISSUE; INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; LIVER HISTOLOGY; LIVER LOBULE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PANCREAS DISEASE; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEXUAL DYSFUNCTION; SKIN DISEASE; SOFT TISSUE DISEASE; TREATMENT DURATION; UROGENITAL TRACT DISEASE; VISUAL DISORDER; ADOLESCENT; BIOPSY; BLOOD; BODY WEIGHT; CLINICAL TRIAL; HEPATITIS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; BODY WEIGHT; CHILD; CYSTEAMINE; CYSTINE DEPLETING AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS; HUMANS; INTENTION TO TREAT ANALYSIS; LIVER; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84997079995     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.08.027     Document Type: Article

References (35)

1. 1 Schwimmer, J.B., Deutsch, R., Kahen, T., et al. Prevalence of fatty liver in children and adolescents. Pediatrics 118 (2006), 1388–1393.
2. 2 Schwimmer, J.B., Behling, C., Newbury, R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42 (2005), 641–649.
3. 3 Schwimmer, J.B., Pardee, P.E., Lavine, J.E., et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 118 (2008), 277–283.
4. 4 Lindback, S.M., Gabbert, C., Johnson, B.L., et al. Pediatric nonalcoholic fatty liver disease: a comprehensive review. Adv Pediatr 57 (2010), 85–140.
5. 5 Jung, D.H., Shim, J.Y., Lee, H.R., et al. Relationship between non-alcoholic fatty liver disease and pulmonary function. Intern Med J 42 (2012), 541–546.
6. 6 Patton, H.M., Yates, K., Unalp-Arida, A., et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 105 (2010), 2093–2102.
7. 7 Rubinstein, E., Lavine, J.E., Schwimmer, J.B., Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis 28 (2008), 380–385.
8. 8 Schwimmer, J.B., Zepeda, A., Newton, K.P., et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One, 9, 2014, e112569.
9. 9 Barshop, N.J., Sirlin, C.B., Schwimmer, J.B., et al. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 28 (2008), 13–24.
10. 10 Videla, L.A., Rodrigo, R., Orellana, M., et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 106 (2005), 261–268.
11. 11 Malaguarnera, L., Madeddu, R., Palio, E., et al. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 42 (2005), 585–591.
12. 12 Lyons, J., Rauh-Pfeiffer, A., Yu, Y., et al. Blood glutathione synthesis rates in healthy adults receiving a sulfur amino acid-free diet. Proc Natl Acad Sci U S A 97 (2000), 5071–5076.
13. 13 Lu, S., Regulation of glutathione synthesis. Curr Top Cell Regul 36 (2002), 95–116.
14. 14 Dohil, R., Cabrera, B.L., Gangoiti, J.A., et al. Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery. Fundam Clin Pharmacol 28 (2014), 136–143.
15. 15 Langman, C.B., Greenbaum, L.A., Sarwal, M., et al. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol 7 (2012), 1112–1120.
16. 16 Maher, P., Lewerenz, J., Lozano, C., et al. A novel approach to enhancing cellular glutathione levels. J Neurochem 107 (2008), 690–700.
17. 17 Dohil, R., Schmeltzer, S., Cabrera, B.L., et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33 (2011), 1036–1044.
18. 18 Gahl, W.A., Thoene, J.G., Schneider, J.A., Cystinosis. N Engl J Med 347 (2002), 111–121.
19. 19 Gangoiti, J.A., Fidler, M., Cabrera, B.L., et al. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study. Br J Clin Pharmacol 70 (2010), 376–382.
20. 20 Berner, M.M., Kriston, L., Bentele, M., et al. The Alcohol Use Disorders Identification Test for detecting at-risk drinking: a systematic review and meta-analysis. J Stud Alcohol Drugs 68 (2006), 461–473.
21. 21 Varni, J.W., Seid, M., Rode, C.A., The PedsQL™: measurement model for the pediatric quality of life inventory. Med Care 37 (1999), 126–139.
22. 22 Kistler, K.D., Molleston, J., Unalp, A., et al. Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 31 (2010), 396–406.
23. 23 Barlow, S.E., Expert, C., Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120:Suppl 4 (2007), S164–S192.
24. 24 Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
25. 25 Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
26. 26 Kleiner, D., Brunt, E., Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 32 (2012), 3–13.
27. 27 Kolsgaard, M., Joner, G., Brunborg, C., et al. Reduction in BMI z-score and improvement in cardiometabolic risk factors in obese children and adolescents. The Oslo Adiposity Intervention Study - a hospital/public health nurse combined treatment. BMC Pediatrics, 11, 2011, 47.
28. 28 Hunt, L., Ford, A., Sabin, M., et al. Clinical measures of adiposity and percentage fat loss: which measure most accurately reflects fat loss and what should we aim for?. Arch Dis Child 92 (2007), 399–403.
29. 29 Stovitz, S., Berge, J., Wetzsteon, R., et al. Stage 1 treatment of pediatric overweight and obesity: a pilot and feasibility randomized controlled trial. Child Obes 10 (2014), 50–57.
30. 30 Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. The TONIC Randomized Controlled Trial. JAMA 305 (2011), 1659–1668.
31. 31 Vuppalanchi, R., Jain, A.K., Deppe, R., et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12 (2014), 2121–2130 e2.
32. 32 Contopoulos-Ioannidis, D.G., Seto, I., Hamm, M.P., et al. Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses. Pediatrics 129 (2012), S161–S184.
33. 33 Xanthakos, S.A., Kohli, R., Pediatric nonalcoholic fatty liver disease: prevalence, diagnosis, risk factors, and management. Clin Liver Dis 1 (2012), 125–128.
34. 34 Weiss, R., Dziura, J., Burgert, T.S., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350 (2004), 2362–2374.
35. 35 Kelly, A., Barlow, S., Rao, G., et al. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. Circulation 128 (2013), 1689–1712.